64,760 Shares in Sanofi (NASDAQ:SNY) Bought by SSA Swiss Advisors AG

Key Points

• SSA Swiss Advisors AG has acquired a new position in Sanofi, purchasing 64,760 shares valued at approximately $3.4 million, which represents 1.7% of their portfolio.
• Several large investors have also increased their stakes in Sanofi, indicating heightened institutional interest in the stock.
• Sanofi has a current consensus rating of "Buy" from analysts, with an average target price of $62.00.

SSA Swiss Advisors AG purchased a new stake in Sanofi (NASDAQ:SNY - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 64,760 shares of the company's stock, valued at approximately $3,406,000. Sanofi comprises 1.7% of SSA Swiss Advisors AG's holdings, making the stock its 17th largest position.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Eastern Bank boosted its holdings in Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after purchasing an additional 300 shares during the period. Bessemer Group Inc. lifted its holdings in shares of Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after acquiring an additional 242 shares during the period. Golden State Wealth Management LLC lifted its holdings in shares of Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after acquiring an additional 545 shares during the period. UMB Bank n.a. lifted its holdings in shares of Sanofi by 30.7% during the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock worth $62,000 after acquiring an additional 264 shares during the period. Finally, Wayfinding Financial LLC bought a new stake in shares of Sanofi during the 1st quarter worth approximately $63,000. Institutional investors and hedge funds own 14.04% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on SNY shares. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. BNP Paribas started coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target for the company. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research note on Monday, June 2nd. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Sanofi presently has an average rating of "Buy" and a consensus target price of $62.00.

Sanofi Stock Up 2.4%

NASDAQ SNY traded up $1.11 on Friday, hitting $46.75. 2,518,877 shares of the company were exchanged, compared to its average volume of 2,122,035. The company has a market cap of $114.65 billion, a PE ratio of 11.24, a PEG ratio of 1.05 and a beta of 0.48. Sanofi has a 12 month low of $44.73 and a 12 month high of $60.12. The stock has a fifty day moving average of $49.21 and a 200-day moving average of $52.09. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.